Clinical trial
Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That…
NCT00025246 · National Cancer Institute (NCI), NIH · Completed
Key facts
| NCT number | NCT00025246 |
|---|---|
| Title | Imatinib Mesylate in Treating Patients With Gastrointestinal Stromal Tumor That Has Been Completely Removed During Surgery |
| Official title | A Phase II Study of Adjuvant STI571 (Gleevec TM) Therapy in Patients Following Completely Resected High-risk Primary GastroIntestinal Stromal Tumor (GIST) |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Gastrointestinal Stromal Tumor |
| Intervention type | Drug, Other |
| Interventions | imatinib mesylate, laboratory biomarker analysis |
| Enrollment | 89 |
| Start date | Sep 1, 2001 |
| Primary completion | Nov 1, 2007 |
| First posted | Jan 27, 2003 |
| Last update posted | Feb 20, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: